Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 413 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sterile Saline injection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

NCT02035605
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

NCT04956575
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Placebo, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
885 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 5, 2026, 6:59 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Th1 Response to Influenza: Aging and Vaccine Efficacy

NCT00396305
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Trivalent Inactivated Influenza
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Persistent Readiness Through Early Prediction Immunization Study

NCT05346302
View directory record Official record
Conditions
Inflammatory Response
Interventions
Pneumovax 23, Typhim VI, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PENG Block for Arthroscopic Hip Surgery

NCT04508504
View directory record Official record
Conditions
Postoperative Pain, Hip Arthroscopy
Interventions
Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline
Procedure · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543268
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass

NCT02236754
View directory record Official record
Conditions
Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions
18 F-FP-DTBZ, PET Scanning
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 5, 2026, 6:59 AM EDT
Recruiting Phase 2 Interventional

Tocilizumab in Lung Transplantation

NCT06033196
View directory record Official record
Conditions
Lung Transplant
Interventions
Tocilizumab, Placebo for Tocilizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)

NCT02105961
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mepolizumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Riverside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 5, 2026, 6:59 AM EDT
Completed No phase listed Observational

Comparison of Epidural and TAP Block in Abdominal Surgery

NCT01848951
View directory record Official record
Conditions
Acute Pain, Surgery, Regional Anesthesia
Interventions
Epidural, TAP Block
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001

NCT02334423
View directory record Official record
Conditions
Glabellar Frown Lines
Interventions
Botulinum toxin, Type A, 0.9% sterile, unpreserved saline
Biological · Other
Lead sponsor
Evolus, Inc.
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

NCT00417417
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 4 Interventional

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

NCT02473952
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
IGIV-C, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B

NCT00764634
View directory record Official record
Conditions
Botulism Vaccine
Interventions
Placebo (USP sterile saline for injection), rBV A/B-40 vaccine
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
Miami, Florida • Pembroke Pines, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2011 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of CSX-1004

NCT06005402
View directory record Official record
Conditions
Opioid Overdose, Opioid Use Disorder
Interventions
CSX-1004, Placebo
Biological
Lead sponsor
Cessation Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

NCT04678830
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Placebos, Leronlimab (700mg)
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Aventura, Florida • Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)

NCT03818737
View directory record Official record
Conditions
Osteoarthritis
Interventions
Bone Marrow Derived MSCs, Adipose-derived MSCs, Umbilical Cord Tissue (UCT) MSCs, Corticosteroid injection
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
40 Years to 70 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Gulf Breeze, Florida • Atlanta, Georgia • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 5, 2026, 6:59 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries

NCT03830775
View directory record Official record
Conditions
Wrist Injuries, PRP
Interventions
Platelet-rich plasma (PRP)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 5, 2026, 6:59 AM EDT
Terminated Phase 2 Interventional Results available

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

NCT02088632
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Incobotulinumtoxina, Placebo Comparator
Biological · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 5, 2026, 6:59 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Neural Mechanism of Aldosterone-induced Insulin Resistance

NCT02102243
View directory record Official record
Conditions
Hypertension
Interventions
DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography
Drug · Procedure
Lead sponsor
Wanpen Vongpatanasin
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 1 Interventional

CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors

NCT00819806
View directory record Official record
Conditions
NY-ESO-1-expressing Tumors
Interventions
Vaccine only, Vaccine + cyclophosphamide
Biological
Lead sponsor
Hassane M. Zarour, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 5, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 5, 2026, 6:59 AM EDT